R. Anthony Williamson, PhD
Co-Founder & CEO
Anthony has over 18 years of experience as a discovery research scientist and entrepreneur, holding leadership positions in academia (The Scripps Research Institute), biotechnology (Prion Solutions, Calmune Corporation) and pharma (Janssen); with a proven ability to evaluate technology, develop strategy and build highly innovative and collaborative international multi-discipline research programs. As Chief Executive Officer, Anthony will define AlphaBiomics' business and technology strategy and coordinate its implementation in an ethical manner, returning value to stakeholders.
Angélique B. van ’t Wout, PhD
Co-Founder & COO
Angélique is an experienced program and project leader, who has worked extensively on the omics of host-pathogen interactions in academia (Universities of Leiden, Amsterdam and Washington) as well as on pre-clinical proof of concept studies for preventive interventions in industry (Janssen). Proven ability to add value along the entire discovery process from conception, fundraising, building and managing teams and collaborations, to execution and reporting. As Chief Operations Officer at AlphaBiomics, Angélique builds the academic and industry partnerships for patient sample collection and data generation.
Marcus Rauch, PhD
Co-Founder & CSO
Marcus is a microbiologist with 18+ years of experience in academia and pharma. He focused his research interest on microbiome sciences while a staff scientist at the University of California, San Francisco. More recently, as a Principal Scientist at Janssen and Head of a microbiome lab, he led a cross-disciplinary team and successfully built and managed internal & external collaborations. Marcus is an author on multiple peer-reviewed publications as well as the recipient of several awards/fellowships. As Chief Scientific Officer at AlphaBiomics, he oversees research operations, defines scientific standards, and sets scientific priorities
Geert R.A.M. D'Haens, MD, PhD
Professor of Gastroenterology,
Amsterdam University Medical Centers (NL)
Prof. D’Haens is a world-renowned gastroenterologist and clinical researcher committed to translate laboratory science for the benefit of patients. He is Founder of the European Crohn’s and Colitis Organization, Director of the European Operations of Robarts Clinical Trials, and Deputy Chairman of the International Organization for the Study of IBD. He spearheads IBD clinical trial design and execution and studies mechanism of action of new IBD drugs and the development of endoscopic endpoints and surrogate markers for IBD.
Georg Zeller, PhD
EMBL, Heidelberg (DE)
Dr. Zeller is a Team leader at the European Molecular Biology Laboratory (EMBL) in Heidelberg. He trained in machine learning with Peer Bork at the Max Planck Institutes and University of Tübingen. His lab develops analysis strategies and tools to investigate how the microbiome contributes to human health, disease progression and treatment success, and how it is shaped by host factors such as nutrition and drug intake. Dr. Zeller led the application of machine learning to microbiome samples identifying bacterial biomarkers for early-stage detection of colorectal cancer.
Karsten Suhre, PhD
Professor of Physiology & Biophysics,
Weill Cornell Medicine - Qatar (QA)
Prof. Suhre is an expert in multi-omics integration using genome-wide association studies (GWAS) with targeted and non-targeted metabolomics. His current research efforts are to translate recent discoveries in metabolomics and genomics to clinical and biomedical application. For this purpose he is setting up and supporting industry-level metabolomics and proteomics facilities in Qatar, conducting clinical studies with metabolomics readouts, mentoring large GWAS with metabolomics and proteomics, and running a bioinformatics core that focuses on whole genome sequencing.